Skip to main content

Table 2 Demographics and clinical findings of RA patients

From: Characterization and use of the ECV304 autoantigenic citrullinome to understand anti-citrullinated protein/peptide autoantibodies in rheumatoid arthritis

 

Derivation (group A)

Validation (group B)

n

RA

n

RA

Age (years, mean ± SD)

87

56.1 ± 13.8

88

57.3 ± 14.2

Female (%)

87

64 (73.6)

88

66 (75)

Serology n (%)

 CCP positive

74

52 (70.3)

78

57 (73.1)

 RF positive

82

48 (58.5)

85

53 (62.4)

 CRPb (mg/L)

63

10.91 ± 22.73

74

7.24 ± 11.86

 Tobacco n (%)

85

22 (25.9)

82

19 (23.5)

 Disease duration (years)

88

11.6 ± 5.8

89

10.3 ± 6.1

 Active diseasea n (%)

81

42 (51.9)

82

37 (45.1)

 RAPID-3 scoresc

71

27 (38)

67

24 (35.8)

 Erosions

82

27 (32.9)

84

25 (29.8)

 Subcutaneous nodules

84

11 (13.1)

88

9 (10.2)

 ILDd

87

4 (4.6)

89

3 (3.4)

Current treatment n (%)

 Biologics

86

36 (41.9)

85

33 (38.8)

 DMARDe

85

78 (91.8)

86

78 (90.7)

 Prednisone > 5 mg

85

6 (7.1)

85

7 (8.2)

 Biologics ever

84

42 (50)

85

41 (48.2)

  1. aActive disease: defined as presence of at least one swollen joint
  2. b CRP C-reactive protein, c RAPID routine assessment of patient index data, d ILD interstitial lung disease, e DMARD disease-modifying antirheumatic drug